anti-EGFR(MicroMedMark)

N/A

Report date: 2022/09/22 20:00:47

Base Information

Drug Nameanti-EGFR(MicroMedMark)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangsu Mingma Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Mingma Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A